Nueli Capital
纽尔利资本
Nueli Capital is a Chinese fund active in growth and secondary-market deals. It has co-led rounds in hard-tech companies such as Xingji, an EDA firm where it partnered with Vertex Growth for a Series B in 2024 , and has re-upped in successive rounds of Aureka Biotechnologies, a generative-antibody drug developer . Elsewhere's corpus also notes its collaboration with SoftBank China Capital on a restructuring S transaction in which Nueli became the sole LP in a continuation vehicle for three remaining portfolio assets, with SoftBank staying on as GP .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
Innovation Often Happens Where No One Has Gone Before | 5Y News Monthly
The big news from last month.
5Y News | Xuanming Life Sciences Closes Tens of Millions of Dollars in Series A Funding
Accelerating the intelligent design of antibodies and the development of innovative pipelines.
Rongbao | Generative AI Powers Industries, Snack Chains Hit 10,000 Stores, Chip Tape-Out Success, Healthcare Goes Global
Innovation lights the path to growth.
Yunqi Capital Portfolio Company Xingji Closes Hundreds-of-Millions RMB Series B Round, Accelerating Growth as an EDA "Chip Power"
Tech Unpacks "Chip" Troubles
Xingji Raises Hundreds of Millions of RMB in Series B to Build Efficient, Intelligent Digital Implementation EDA Platform
Smart, Speedy, Simple
The Making of a Restructuring S Deal
New Alliance has partnered with SBCVC.
